Lehrstuhl für Innere Medizin III

Reconstruction of the miR-506-Quaking axis in Idiopathic Pulmonary Fibrosis using integrative multi-source bioinformatics (2021) Stojanović SD, Fuchs M, Liang C, Schmidt K, Xiao K, Just A, Pfanne A, et al. Journal article Does methotrexate influence COVID-19 infection? Case series and mechanistic data (2021) Schaelter F, Dürholz K, Bucci L, Burmester G, Caporali R, Figuereido C, Cobra JF, et al. Journal article Accuracy, patient-perceived usability, and acceptance of two symptom checkers (Ada and Rheport) in rheumatology: interim results from a randomized controlled crossover trial (2021) Knitza J, Mohn J, Bergmann C, Kampylafka E, Hagen M, Bohr D, Morf H, et al. Journal article Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs (2021) Vodencarevic A, Tascilar K, Reiser M, Hueber A, Haschka J, Bayat S, Meinderink T, et al. Journal article Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis (2021) Valor-Méndez L, Kleyer A, Rech J, Manger B, Schett G Journal article Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections (2021) Bénard A, Jacobsen A, Brunner M, Krautz C, Klösch B, Swierzy I, Naschberger E, et al. Journal article Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study (2021) Štorkánová H, Oreská S, Špiritović M, Heřmánková B, Bubová K, Komarc M, Pavelka K, et al. Journal article Epigenetic profiling of twins identify repression of KLF4 as a novel pathomechanism in systemic sclerosis (2021) Distler J, O'Reilly S Journal article, Editorial Purinergic signalling in systemic sclerosis (2021) Hoeppner J, Bruni C, Distler O, Robson SC, Burmester GR, Siegert E, Distler J Journal article, Review article Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS) (2021) Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, Shawi M, et al. Journal article